Phaseline

Companies › Cerevance

Cerevance: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CVN424–Phase 3Parkinson Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06553027CVN424Phase 3Parkinson DiseaseNeurologyAug 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Prilenia Ambros Therapeutics Green Valley (Shanghai) Pharmaceuticals CereMark Pharma MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.